BioSpecifics Reports Second Quarter 2020 Financial and Operating Results

WILMINGTON, Del., Aug. 10, 2020 /PRNewswire/ — BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced its financial results for the second quarter ended June 30, 2020.
“While we anticipated an impact on second quarter 2020 royalty revenue due to COVID-19, our cash position remains strong, and we are pro…

Click here to view the original article.